4-Phenylbutyric Acid
The therapeutic efficacy of Phenylbutyric acid can be decreased when used in combination with Fluocinonide.
Aceclofenac
The risk or severity of adverse effects can be increased when Aceclofenac is combined with Fluocinonide.
Acemetacin
The risk or severity of adverse effects can be increased when Acemetacin is combined with Fluocinonide.
Advertisement
Acetaminophen
The risk or severity of adverse effects can be increased when Fluocinonide is combined with Acetaminophen.
Acetyl salicylate
The risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Fluocinonide.
Adapalene
The risk or severity of adverse effects can be increased when Adapalene is combined with Fluocinonide.
Advertisement
Aldesleukin
Fluocinonide may decrease the antineoplastic activities of Aldesleukin.
Alminoprofen
The risk or severity of adverse effects can be increased when Alminoprofen is combined with Fluocinonide.
Aloglutamol
The bioavailability of Fluocinonide can be decreased when combined with Aloglutamol.
Advertisement
Aloxiprin
The risk or severity of adverse effects can be increased when Aloxiprin is combined with Fluocinonide.
Aluminum
The bioavailability of Fluocinonide can be decreased when combined with Aluminium.
Aluminum Hydroxide
The bioavailability of Fluocinonide can be decreased when combined with Aluminum hydroxide.
aluminum hydroxide, dried (USP)
The bioavailability of Fluocinonide can be decreased when combined with Aluminum hydroxide.
Aluminum Magnesium Silicate
The bioavailability of Fluocinonide can be decreased when combined with Almasilate.
Ambenonium
The risk or severity of adverse effects can be increased when Fluocinonide is combined with Ambenonium.
Aminosalicylic Acid
The risk or severity of adverse effects can be increased when Aminosalicylic Acid is combined with Fluocinonide.
Amiodarone
The serum concentration of Fluocinonide can be increased when it is combined with Amiodarone.
Amphotericin B
Fluocinonide may increase the hypokalemic activities of Amphotericin B.
amphotericin B liposomal
Fluocinonide may increase the hypokalemic activities of Amphotericin B.
Anthrax immune globulin, human
The risk or severity of adverse effects can be increased when Fluocinonide is combined with Anthrax immune globulin human.
Antipyrine
The risk or severity of adverse effects can be increased when Antipyrine is combined with Fluocinonide.
Apalutamide
The serum concentration of Fluocinonide can be decreased when it is combined with Apalutamide.
Apazone
The risk or severity of adverse effects can be increased when Azapropazone is combined with Fluocinonide.
Apremilast
The risk or severity of adverse effects can be increased when Apremilast is combined with Fluocinonide.
Aprepitant
The serum concentration of Fluocinonide can be increased when it is combined with Aprepitant.
Asian ginseng extract
The risk or severity of adverse effects can be increased when Fluocinonide is combined with Ginseng.
Aspirin
The risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Fluocinonide.
Atazanavir
The serum concentration of Fluocinonide can be increased when it is combined with Atazanavir.
Atracurium Besylate
Atracurium besylate may increase the adverse neuromuscular activities of Fluocinonide.
Azelastine
The risk or severity of adverse effects can be increased when Azelastine is combined with Fluocinonide.
Azosemide
Fluocinonide may increase the hypokalemic activities of Azosemide.
Balsalazide
The risk or severity of adverse effects can be increased when Balsalazide is combined with Fluocinonide.
Bazedoxifene
The serum concentration of Fluocinonide can be increased when it is combined with Bazedoxifene.
BCG Vaccine
The risk or severity of adverse effects can be increased when Fluocinonide is combined with BCG vaccine.
BCG, Live, Connaught Strain
The risk or severity of adverse effects can be increased when Fluocinonide is combined with Bacillus calmette-guerin substrain connaught live antigen.
BCG, Live, Tice Strain
The risk or severity of adverse effects can be increased when Fluocinonide is combined with Bacillus calmette-guerin substrain tice live antigen.
Bendroflumethiazide
Fluocinonide may increase the hypokalemic activities of Bendroflumethiazide.
Benzoic Acid
The therapeutic efficacy of Benzoic Acid can be decreased when used in combination with Fluocinonide.
Benzthiazide
Fluocinonide may increase the hypokalemic activities of Benzthiazide.
Benzydamine
The risk or severity of adverse effects can be increased when Benzydamine is combined with Fluocinonide.
Bismuth Subcitrate
The bioavailability of Fluocinonide can be decreased when combined with Bismuth Subcitrate.
Bismuth Subnitrate
The bioavailability of Fluocinonide can be decreased when combined with Bismuth subnitrate.
Boceprevir
The serum concentration of Fluocinonide can be increased when it is combined with Boceprevir.
Bromfenac
The risk or severity of adverse effects can be increased when Bromfenac is combined with Fluocinonide.
Bufexamac
The risk or severity of adverse effects can be increased when Bufexamac is combined with Fluocinonide.
Bumetanide
Fluocinonide may increase the hypokalemic activities of Bumetanide.
Calcitriol
The therapeutic efficacy of Calcitriol can be decreased when used in combination with Fluocinonide.
Calcium Carbonate
The bioavailability of Fluocinonide can be decreased when combined with Calcium Carbonate.
CALCIUM CARBONATE, PRECIPITATED
The bioavailability of Fluocinonide can be decreased when combined with Calcium Carbonate.
Capromab Pendetide
Fluocinonide may decrease effectiveness of Capromab pendetide as a diagnostic agent.
Capsaicin
The risk or severity of adverse effects can be increased when Fluocinonide is combined with Capsaicin.
Carbamazepine
The serum concentration of Fluocinonide can be decreased when it is combined with Carbamazepine.
Carprofen
The risk or severity of adverse effects can be increased when Carprofen is combined with Fluocinonide.
Celecoxib
The risk or severity of adverse effects can be increased when Celecoxib is combined with Fluocinonide.
Ceritinib
Fluocinonide may increase the hyperglycemic activities of Ceritinib.
Chloroquine
The risk or severity of adverse effects can be increased when Chloroquine is combined with Fluocinonide.
Chlorothiazide
Fluocinonide may increase the hypokalemic activities of Chlorothiazide.
Chlorotrianisene
The serum concentration of Fluocinonide can be increased when it is combined with Chlorotrianisene.
Chlorphenesin
The risk or severity of adverse effects can be increased when Fluocinonide is combined with Chlorphenesin.
Chlorthalidone
Fluocinonide may increase the hypokalemic activities of Chlorthalidone.
Cholestyramine Resin
Cholestyramine can cause a decrease in the absorption of Fluocinonide resulting in a reduced serum concentration and potentially a decrease in efficacy.
Choline Magnesium Trisalicyclate
The risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Fluocinonide.
Cinoxacin
The risk or severity of adverse effects can be increased when Fluocinonide is combined with Cinoxacin.
Ciprofloxacin
The risk or severity of adverse effects can be increased when Fluocinonide is combined with Ciprofloxacin.
Cisplatin
The risk or severity of adverse effects can be increased when Fluocinonide is combined with Cisplatin.
Clarithromycin
The serum concentration of Fluocinonide can be increased when it is combined with Clarithromycin.
Clodronic Acid
The risk or severity of adverse effects can be increased when Fluocinonide is combined with Clodronic Acid.
Clonixin
The risk or severity of adverse effects can be increased when Clonixin is combined with Fluocinonide.
Cobicistat
The serum concentration of Fluocinonide can be increased when it is combined with Cobicistat.
Colesevelam
Colesevelam can cause a decrease in the absorption of Fluocinonide resulting in a reduced serum concentration and potentially a decrease in efficacy.
Colestipol
Colestipol can cause a decrease in the absorption of Fluocinonide resulting in a reduced serum concentration and potentially a decrease in efficacy.
Corticorelin Ovine
The therapeutic efficacy of Corticorelin ovine triflutate can be decreased when used in combination with Fluocinonide.
Corticorelin Ovine Triflutate
The therapeutic efficacy of Corticorelin ovine triflutate can be decreased when used in combination with Fluocinonide.
Curcumin
The risk or severity of adverse effects can be increased when Curcumin is combined with Fluocinonide.
Cyclopenthiazide
Fluocinonide may increase the hypokalemic activities of Cyclopenthiazide.
Danazol
Fluocinonide may increase the fluid retaining activities of Danazol.
Darunavir
The serum concentration of Fluocinonide can be increased when it is combined with Darunavir.
Deferasirox
The risk or severity of adverse effects can be increased when Fluocinonide is combined with Deferasirox.
Demecarium
The risk or severity of adverse effects can be increased when Fluocinonide is combined with Demecarium.
Dexketoprofen
The risk or severity of adverse effects can be increased when Fluocinonide is combined with Dexketoprofen.
Diclofenac
The risk or severity of adverse effects can be increased when Diclofenac is combined with Fluocinonide.
Dienestrol
The serum concentration of Fluocinonide can be increased when it is combined with Dienestrol.
Diethylstilbestrol
The serum concentration of Fluocinonide can be increased when it is combined with Diethylstilbestrol.
Diflunisal
The risk or severity of adverse effects can be increased when Diflunisal is combined with Fluocinonide.
Dipivefrin
The risk or severity of adverse effects can be increased when Fluocinonide is combined with Dipivefrin.
Dipyrone
The risk or severity of adverse effects can be increased when Metamizole is combined with Fluocinonide.
Distigmine
The risk or severity of adverse effects can be increased when Fluocinonide is combined with Distigmine.
Donepezil
The risk or severity of adverse effects can be increased when Fluocinonide is combined with Donepezil.
Drospirenone
The risk or severity of adverse effects can be increased when Fluocinonide is combined with Drospirenone.
Droxicam
The risk or severity of adverse effects can be increased when Droxicam is combined with Fluocinonide.
Echothiophate
The risk or severity of adverse effects can be increased when Fluocinonide is combined with Echothiophate.
Edrophonium
The risk or severity of adverse effects can be increased when Fluocinonide is combined with Edrophonium.
Eicosapentaenoic Acid
The risk or severity of adverse effects can be increased when Fluocinonide is combined with Icosapent.
Enoxacin
The risk or severity of adverse effects can be increased when Fluocinonide is combined with Enoxacin.
Enzalutamide
The serum concentration of Fluocinonide can be decreased when it is combined with Enzalutamide.
Equol, (-)-
The serum concentration of Fluocinonide can be increased when it is combined with Equol.
Estradiol
The serum concentration of Fluocinonide can be increased when it is combined with Estradiol.
Estradiol acetate
The serum concentration of Fluocinonide can be increased when it is combined with Estradiol acetate.
Estradiol Cypionate
The serum concentration of Fluocinonide can be increased when it is combined with Estradiol cypionate.
Estradiol Valerate
The serum concentration of Fluocinonide can be increased when it is combined with Estradiol valerate.
Estriol
The serum concentration of Fluocinonide can be increased when it is combined with Estriol.
Estrogens, Conjugated (USP)
The serum concentration of Fluocinonide can be increased when it is combined with Conjugated estrogens.
Estrogens, Esterified (USP)
The serum concentration of Fluocinonide can be increased when it is combined with Estrogens, esterified.
Estrone
The serum concentration of Fluocinonide can be increased when it is combined with Estrone.
Etanercept
The risk or severity of adverse effects can be increased when Etanercept is combined with Fluocinonide.
Ethacrynate
Fluocinonide may increase the hypokalemic activities of Etacrynic acid.
Ethacrynic Acid
Fluocinonide may increase the hypokalemic activities of Etacrynic acid.
Ethinyl Estradiol
The serum concentration of Fluocinonide can be increased when it is combined with Ethinyl Estradiol.
Etodolac
The risk or severity of adverse effects can be increased when Etodolac is combined with Fluocinonide.
Etofenamate
The risk or severity of adverse effects can be increased when Etofenamate is combined with Fluocinonide.
Etoricoxib
The risk or severity of adverse effects can be increased when Etoricoxib is combined with Fluocinonide.
Evening primrose oil
The risk or severity of adverse effects can be increased when Evening primrose oil is combined with Fluocinonide.
Felbinac
The risk or severity of adverse effects can be increased when Felbinac is combined with Fluocinonide.
Fenbufen
The risk or severity of adverse effects can be increased when Fenbufen is combined with Fluocinonide.
Fenoprofen
The risk or severity of adverse effects can be increased when Fenoprofen is combined with Fluocinonide.
Ferulic Acid
The risk or severity of adverse effects can be increased when Ferulic acid is combined with Fluocinonide.
Fish Oils
The risk or severity of adverse effects can be increased when Fluocinonide is combined with Fish oil.
Fleroxacin
The risk or severity of adverse effects can be increased when Fluocinonide is combined with Fleroxacin.
Floctafenine
The risk or severity of adverse effects can be increased when Floctafenine is combined with Fluocinonide.
Flumequine
The risk or severity of adverse effects can be increased when Fluocinonide is combined with Flumequine.
Fluoxymesterone
Fluocinonide may increase the fluid retaining activities of Fluoxymesterone.
Flurbiprofen
The risk or severity of adverse effects can be increased when Flurbiprofen is combined with Fluocinonide.
Fosaprepitant
The serum concentration of Fluocinonide can be increased when it is combined with Fosaprepitant.
Fosphenytoin
The serum concentration of Fluocinonide can be decreased when it is combined with Fosphenytoin.
Furosemide
Fluocinonide may increase the hypokalemic activities of Furosemide.
Galantamine
The risk or severity of adverse effects can be increased when Fluocinonide is combined with Galantamine.
Gallamine Triethiodide
The risk or severity of adverse effects can be increased when Fluocinonide is combined with Gallamine Triethiodide.
Gatifloxacin
The risk or severity of adverse effects can be increased when Fluocinonide is combined with Gatifloxacin.
Gatifloxacin Anhydrous
The risk or severity of adverse effects can be increased when Fluocinonide is combined with Gatifloxacin.
Gemifloxacin
The risk or severity of adverse effects can be increased when Fluocinonide is combined with Gemifloxacin.
Gemifloxacin Mesylate
The risk or severity of adverse effects can be increased when Fluocinonide is combined with Gemifloxacin.
Genistein
The serum concentration of Fluocinonide can be increased when it is combined with Genistein.
Ginkgo biloba extract
The risk or severity of adverse effects can be increased when Fluocinonide is combined with Ginkgo biloba.
Ginseng Preparation
The risk or severity of adverse effects can be increased when Fluocinonide is combined with Ginseng.
Glycerol Phenylbutyrate
The therapeutic efficacy of Glycerol Phenylbutyrate can be decreased when used in combination with Fluocinonide.
Grepafloxacin
The risk or severity of adverse effects can be increased when Fluocinonide is combined with Grepafloxacin.
Hepatitis A Vaccine, Inactivated
The risk or severity of adverse effects can be increased when Fluocinonide is combined with Hepatitis A Vaccine.
Hepatitis B Surface Antigen Vaccine
The risk or severity of adverse effects can be increased when Fluocinonide is combined with Hepatitis B Vaccine (Recombinant).
Hyaluronidase
The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Fluocinonide.
Hyaluronidase, Ovine
The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Fluocinonide.
Hydrochlorothiazide
Fluocinonide may increase the hypokalemic activities of Hydrochlorothiazide.
Hydroflumethiazide
Fluocinonide may increase the hypokalemic activities of Hydroflumethiazide.
Hydrotalcite
The bioavailability of Fluocinonide can be decreased when combined with Hydrotalcite.
Hypoxis hemerocallidea root extract
The serum concentration of Fluocinonide can be decreased when it is combined with St. John's Wort.
Ibuprofen
The risk or severity of adverse effects can be increased when Ibuprofen is combined with Fluocinonide.
Icatibant
The risk or severity of adverse effects can be increased when Icatibant is combined with Fluocinonide.
Idelalisib
The serum concentration of Fluocinonide can be increased when it is combined with Idelalisib.
Indacaterol
Indacaterol may increase the hypokalemic activities of Fluocinonide.
Indapamide
Fluocinonide may increase the hypokalemic activities of Indapamide.
Indinavir
The serum concentration of Fluocinonide can be increased when it is combined with Indinavir.
INDINAVIR ANHYDROUS
The serum concentration of Fluocinonide can be increased when it is combined with Indinavir.
Indobufen
The risk or severity of adverse effects can be increased when Indobufen is combined with Fluocinonide.
Indomethacin
The risk or severity of adverse effects can be increased when Indomethacin is combined with Fluocinonide.
Isoflurophate
The risk or severity of adverse effects can be increased when Fluocinonide is combined with Isoflurophate.
Isoniazid
The serum concentration of Isoniazid can be decreased when it is combined with Fluocinonide.
Itraconazole
The serum concentration of Fluocinonide can be increased when it is combined with Itraconazole.
Kebuzone
The risk or severity of adverse effects can be increased when Kebuzone is combined with Fluocinonide.
Ketoconazole
The serum concentration of Fluocinonide can be increased when it is combined with Ketoconazole.
Ketoprofen
The risk or severity of adverse effects can be increased when Ketoprofen is combined with Fluocinonide.
Ketorolac
The risk or severity of adverse effects can be increased when Ketorolac is combined with Fluocinonide.
Korean ginseng preparation
The risk or severity of adverse effects can be increased when Fluocinonide is combined with Ginseng.
KOREAN GINSENG ROOT
The risk or severity of adverse effects can be increased when Fluocinonide is combined with Ginseng.
Korean Ginseng Root Extract
The risk or severity of adverse effects can be increased when Fluocinonide is combined with Ginseng.
Lacidipine
The serum concentration of Lacidipine can be decreased when it is combined with Fluocinonide.
Leflunomide
The risk or severity of adverse effects can be increased when Leflunomide is combined with Fluocinonide.
Levofloxacin
The risk or severity of adverse effects can be increased when Fluocinonide is combined with Levofloxacin.
Levofloxacin Anhydrous
The risk or severity of adverse effects can be increased when Fluocinonide is combined with Levofloxacin.
Limonene, (+)-
The risk or severity of adverse effects can be increased when (4R)-limonene is combined with Fluocinonide.
Lomefloxacin
The risk or severity of adverse effects can be increased when Fluocinonide is combined with Lomefloxacin.
Lopinavir
The serum concentration of Fluocinonide can be increased when it is combined with Lopinavir.
Lornoxicam
The risk or severity of adverse effects can be increased when Lornoxicam is combined with Fluocinonide.
Loxoprofen
The risk or severity of adverse effects can be increased when Loxoprofen is combined with Fluocinonide.
Lumacaftor
The serum concentration of Fluocinonide can be decreased when it is combined with Lumacaftor.
Magaldrate
The bioavailability of Fluocinonide can be decreased when combined with Magaldrate.
Magnesium Carbonate
The bioavailability of Fluocinonide can be decreased when combined with Magnesium carbonate.
Magnesium Hydroxide
The bioavailability of Fluocinonide can be decreased when combined with Magnesium hydroxide.
Magnesium Oxide
The bioavailability of Fluocinonide can be decreased when combined with Magnesium oxide.
Magnesium Salicylate
The risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Fluocinonide.
Magnesium silicate
The bioavailability of Fluocinonide can be decreased when combined with Magnesium silicate.
Magnesium Trisilicate
The bioavailability of Fluocinonide can be decreased when combined with Magnesium Trisilicate.
Malathion
The risk or severity of adverse effects can be increased when Fluocinonide is combined with Malathion.
Masoprocol
The risk or severity of adverse effects can be increased when Masoprocol is combined with Fluocinonide.
Meclofenamate
The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Fluocinonide.
Meclofenamic Acid
The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Fluocinonide.
Mefenamic Acid
The risk or severity of adverse effects can be increased when Mefenamic acid is combined with Fluocinonide.
Mefloquine
The risk or severity of adverse effects can be increased when Fluocinonide is combined with Mefloquine.
Meloxicam
The risk or severity of adverse effects can be increased when Meloxicam is combined with Fluocinonide.
Memantine
The risk or severity of adverse effects can be increased when Fluocinonide is combined with Memantine.
Mesalamine
The risk or severity of adverse effects can be increased when Mesalazine is combined with Fluocinonide.
Mesterolone
Fluocinonide may increase the fluid retaining activities of Mesterolone.
Mestranol
The serum concentration of Fluocinonide can be increased when it is combined with Mestranol.
Methyclothiazide
Fluocinonide may increase the hypokalemic activities of Methyclothiazide.
Methyl Salicylate
The risk or severity of adverse effects can be increased when Methyl salicylate is combined with Fluocinonide.
Methyltestosterone
Fluocinonide may increase the fluid retaining activities of Methyltestosterone.
Metoclopramide
The risk or severity of adverse effects can be increased when Fluocinonide is combined with Metoclopramide.
Metolazone
Fluocinonide may increase the hypokalemic activities of Metolazone.
Mifepristone
The therapeutic efficacy of Fluocinonide can be decreased when used in combination with Mifepristone.
Minaprine
The risk or severity of adverse effects can be increased when Fluocinonide is combined with Minaprine.
Mitotane
The serum concentration of Fluocinonide can be decreased when it is combined with Mitotane.
Mivacurium
Mivacurium may increase the adverse neuromuscular activities of Fluocinonide.
Morniflumate
The risk or severity of adverse effects can be increased when Fluocinonide is combined with Morniflumate.
Moxifloxacin
The risk or severity of adverse effects can be increased when Fluocinonide is combined with Moxifloxacin.
MYCOPHENOLATE
The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Fluocinonide.
Mycophenolate Mofetil
The risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Fluocinonide.
Mycophenolic Acid
The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Fluocinonide.
Nabumetone
The risk or severity of adverse effects can be increased when Nabumetone is combined with Fluocinonide.
Naftifine
The risk or severity of adverse effects can be increased when Naftifine is combined with Fluocinonide.
Nalidixic Acid
The risk or severity of adverse effects can be increased when Fluocinonide is combined with Nalidixic Acid.
Nandrolone
Fluocinonide may increase the fluid retaining activities of Nandrolone.
Nandrolone Decanoate
Fluocinonide may increase the fluid retaining activities of Nandrolone decanoate.
Naproxen
The risk or severity of adverse effects can be increased when Naproxen is combined with Fluocinonide.
Nefazodone
The serum concentration of Fluocinonide can be increased when it is combined with Nefazodone.
Nelfinavir
The serum concentration of Fluocinonide can be increased when it is combined with Nelfinavir.
Neostigmine
The risk or severity of adverse effects can be increased when Fluocinonide is combined with Neostigmine.
Nepafenac
The risk or severity of adverse effects can be increased when Nepafenac is combined with Fluocinonide.
Nevirapine
The serum concentration of Fluocinonide can be decreased when it is combined with Nevirapine.
Nicorandil
The risk or severity of adverse effects can be increased when Fluocinonide is combined with Nicorandil.
Niflumic Acid
The risk or severity of adverse effects can be increased when Niflumic Acid is combined with Fluocinonide.
Nimesulide
The risk or severity of adverse effects can be increased when Nimesulide is combined with Fluocinonide.
Norfloxacin
The risk or severity of adverse effects can be increased when Fluocinonide is combined with Norfloxacin.
O-PHENANTHROLINE
The risk or severity of adverse effects can be increased when Fluocinonide is combined with 1,10-Phenanthroline.
Oenothera biennis seed extract
The risk or severity of adverse effects can be increased when Evening primrose oil is combined with Fluocinonide.
Ofloxacin
The risk or severity of adverse effects can be increased when Fluocinonide is combined with Ofloxacin.
Olopatadine
The risk or severity of adverse effects can be increased when Olopatadine is combined with Fluocinonide.
Olsalazine
The risk or severity of adverse effects can be increased when Olsalazine is combined with Fluocinonide.
Oxandrolone
Fluocinonide may increase the fluid retaining activities of Oxandrolone.
Oxaprozin
The risk or severity of adverse effects can be increased when Oxaprozin is combined with Fluocinonide.
Oxymetholone
Fluocinonide may increase the fluid retaining activities of Oxymetholone.
Oxyphenbutazone
The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Fluocinonide.
Palmidrol
The risk or severity of adverse effects can be increased when Palmidrol is combined with Fluocinonide.
Parecoxib
The risk or severity of adverse effects can be increased when Parecoxib is combined with Fluocinonide.
Parthenolide
The risk or severity of adverse effects can be increased when Parthenolide is combined with Fluocinonide.
Pefloxacin
The risk or severity of adverse effects can be increased when Fluocinonide is combined with Pefloxacin.
Pentobarbital
The serum concentration of Fluocinonide can be decreased when it is combined with Pentobarbital.
Phenobarbital
The serum concentration of Fluocinonide can be decreased when it is combined with Phenobarbital.
Phenylacetic Acid
The therapeutic efficacy of Phenylacetic acid can be decreased when used in combination with Fluocinonide.
Phenylbutazone
The risk or severity of adverse effects can be increased when Phenylbutazone is combined with Fluocinonide.
Phenylbutyrate
The therapeutic efficacy of Phenylbutyric acid can be decreased when used in combination with Fluocinonide.
Phenytoin
The serum concentration of Fluocinonide can be decreased when it is combined with Phenytoin.
Physostigmine
The risk or severity of adverse effects can be increased when Fluocinonide is combined with Physostigmine.
Pimecrolimus
The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Fluocinonide.
Piretanide
Fluocinonide may increase the hypokalemic activities of Piretanide.
Pirfenidone
The risk or severity of adverse effects can be increased when Pirfenidone is combined with Fluocinonide.
Piroxicam
The risk or severity of adverse effects can be increased when Piroxicam is combined with Fluocinonide.
Piroxicam-Beta-Cyclodextrin
The risk or severity of adverse effects can be increased when Piroxicam is combined with Fluocinonide.
Polyestradiol Phosphate
The serum concentration of Fluocinonide can be increased when it is combined with Polyestradiol phosphate.
Polythiazide
Fluocinonide may increase the hypokalemic activities of Polythiazide.
Pomalidomide
The risk or severity of adverse effects can be increased when Fluocinonide is combined with Pomalidomide.
Posaconazole
The serum concentration of Fluocinonide can be increased when it is combined with Posaconazole.
Primidone
The serum concentration of Fluocinonide can be decreased when it is combined with Primidone.
Promestriene
The serum concentration of Fluocinonide can be increased when it is combined with Promestriene.
Pyridostigmine
The risk or severity of adverse effects can be increased when Fluocinonide is combined with Pyridostigmine.
Pyridostigmine Bromide
The risk or severity of adverse effects can be increased when Fluocinonide is combined with Pyridostigmine.
Quinestrol
The serum concentration of Fluocinonide can be increased when it is combined with Quinestrol.
Quinethazone
Fluocinonide may increase the hypokalemic activities of Quinethazone.
Rabies Immune Globulin, Human
The risk or severity of adverse effects can be increased when Fluocinonide is combined with Human rabies virus immune globulin.
Rabies Virus Vaccine Flury-Lep Strain
The risk or severity of adverse effects can be increased when Fluocinonide is combined with Rabies virus inactivated antigen, A.
Rapacuronium
Rapacuronium may increase the adverse neuromuscular activities of Fluocinonide.
Resveratrol
The risk or severity of adverse effects can be increased when Resveratrol is combined with Fluocinonide.
Rifabutin
The serum concentration of Fluocinonide can be decreased when it is combined with Rifabutin.
Rifampin
The serum concentration of Fluocinonide can be decreased when it is combined with Rifampicin.
Rifapentine
The serum concentration of Fluocinonide can be decreased when it is combined with Rifapentine.
Rivastigmine
The risk or severity of adverse effects can be increased when Fluocinonide is combined with Rivastigmine.
Rofecoxib
The risk or severity of adverse effects can be increased when Rofecoxib is combined with Fluocinonide.
Rosoxacin
The risk or severity of adverse effects can be increased when Fluocinonide is combined with Rosoxacin.
ROTAVIRUS VACCINE, LIVE
The risk or severity of adverse effects can be increased when Fluocinonide is combined with Rotavirus Vaccine.
Rubella Virus Vaccine Live (wistar Ra 27-3 Strain)
The risk or severity of adverse effects can be increased when Fluocinonide is combined with Rubella virus vaccine.
Salicylamide
The risk or severity of adverse effects can be increased when Salicylamide is combined with Fluocinonide.
Salicylic Acid
The risk or severity of adverse effects can be increased when Salicylic acid is combined with Fluocinonide.
Salmonella enterica subsp. enterica serovar typhi
The risk or severity of adverse effects can be increased when Fluocinonide is combined with Salmonella typhi ty21a live antigen.
Salsalate
The risk or severity of adverse effects can be increased when Salsalate is combined with Fluocinonide.
Saquinavir
The serum concentration of Fluocinonide can be increased when it is combined with Saquinavir.
Saquinavir Mesylate
The serum concentration of Fluocinonide can be increased when it is combined with Saquinavir.
Serratiopeptidase
The risk or severity of adverse effects can be increased when Serrapeptase is combined with Fluocinonide.
Sodium Bicarbonate
The bioavailability of Fluocinonide can be decreased when combined with Sodium bicarbonate.
Sparfloxacin
The risk or severity of adverse effects can be increased when Fluocinonide is combined with Sparfloxacin.
ST. JOHN'S WORT EXTRACT
The serum concentration of Fluocinonide can be decreased when it is combined with St. John's Wort.
Stanozolol
Fluocinonide may increase the fluid retaining activities of Stanozolol.
Sulfasalazine
The risk or severity of adverse effects can be increased when Sulfasalazine is combined with Fluocinonide.
Sulindac
The risk or severity of adverse effects can be increased when Sulindac is combined with Fluocinonide.
Suprofen
The risk or severity of adverse effects can be increased when Suprofen is combined with Fluocinonide.
synthetic conjugated estrogens, A
The serum concentration of Fluocinonide can be increased when it is combined with Synthetic Conjugated Estrogens, A.
synthetic conjugated estrogens, B
The serum concentration of Fluocinonide can be increased when it is combined with Synthetic Conjugated Estrogens, B.
Tacrine
The risk or severity of adverse effects can be increased when Fluocinonide is combined with Tacrine.
Talniflumate
The risk or severity of adverse effects can be increased when Fluocinonide is combined with Talniflumate.
Telaprevir
The serum concentration of Telaprevir can be decreased when it is combined with Fluocinonide.
Telithromycin
The serum concentration of Fluocinonide can be increased when it is combined with Telithromycin.
Temafloxacin
The risk or severity of adverse effects can be increased when Fluocinonide is combined with Temafloxacin.
Tenoxicam
The risk or severity of adverse effects can be increased when Tenoxicam is combined with Fluocinonide.
Teriflunomide
The risk or severity of adverse effects can be increased when Teriflunomide is combined with Fluocinonide.
Testosterone
Fluocinonide may increase the fluid retaining activities of Testosterone.
Testosterone Cypionate
The risk or severity of edema formation can be increased when Testosterone cypionate is combined with Fluocinonide.
Testosterone Enanthate
The risk or severity of edema formation can be increased when Testosterone enanthate is combined with Fluocinonide.
Testosterone Propionate
Fluocinonide may increase the fluid retaining activities of Testosterone propionate.
Testosterone Undecanoate
The risk or severity of fluid retention can be increased when Testosterone undecanoate is combined with Fluocinonide.
Tetanus Toxoid Vaccine, Inactivated
The risk or severity of adverse effects can be increased when Fluocinonide is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated).
Tiaprofenic Acid
The risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Fluocinonide.
Tibolone
The serum concentration of Fluocinonide can be increased when it is combined with Tibolone.
Tolfenamic Acid
The risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Fluocinonide.
Tolmetin
The risk or severity of adverse effects can be increased when Tolmetin is combined with Fluocinonide.
Torsemide
Fluocinonide may increase the hypokalemic activities of Torasemide.
Tranilast
The risk or severity of adverse effects can be increased when Tranilast is combined with Fluocinonide.
Triamcinolone
The risk or severity of adverse effects can be increased when Fluocinonide is combined with Triamcinolone.
Tribenoside
The risk or severity of adverse effects can be increased when Tribenoside is combined with Fluocinonide.
Trichlormethiazide
Fluocinonide may increase the hypokalemic activities of Trichlormethiazide.
Trolamine Salicylate
The risk or severity of adverse effects can be increased when Trolamine salicylate is combined with Fluocinonide.
Tromethamine
The bioavailability of Fluocinonide can be decreased when combined with Tromethamine.
Trovafloxacin
The risk or severity of adverse effects can be increased when Fluocinonide is combined with Trovafloxacin.
Tubocurarine
The risk or severity of adverse effects can be increased when Fluocinonide is combined with Tubocurarine.
Typhoid Vaccine Live Ty21a
The risk or severity of adverse effects can be increased when Fluocinonide is combined with Salmonella typhi ty21a live antigen.
Typhoid Vi Polysaccharide Vaccine, S typhi Ty2 strain
The risk or severity of adverse effects can be increased when Fluocinonide is combined with Salmonella typhi ty2 vi polysaccharide antigen.
Tyrothricin
The risk or severity of adverse effects can be increased when Fluocinonide is combined with Tyrothricin.
Valdecoxib
The risk or severity of adverse effects can be increased when Valdecoxib is combined with Fluocinonide.
Varicella Virus Vaccine Live (Oka-Merck) strain
The risk or severity of adverse effects can be increased when Fluocinonide is combined with Varicella Zoster Vaccine (Live/Attenuated).
Voriconazole
The serum concentration of Fluocinonide can be increased when it is combined with Voriconazole.
Warfarin
Fluocinonide may increase the anticoagulant activities of Warfarin.
Yellow Fever Vaccine
The risk or severity of adverse effects can be increased when Fluocinonide is combined with Yellow Fever Vaccine.
Yellow-Fever Virus Vaccine, 17D-204 strain
The risk or severity of adverse effects can be increased when Fluocinonide is combined with Yellow Fever Vaccine.
Zileuton
The risk or severity of adverse effects can be increased when Zileuton is combined with Fluocinonide.
Zomepirac
The risk or severity of adverse effects can be increased when Zomepirac is combined with Fluocinonide.
